SequelSEC

Keros Therapeutics, Inc. KROS

Pharmaceutical Preparations · CIK 0001664710 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$243.86M
Fiscal year ended 2025-12-31
Operating income
$67.57M
Fiscal year ended 2025-12-31
Free cash flow
$105.95M
Fiscal year ended 2025-12-31

Keros Therapeutics, Inc. (KROS) reported revenue of $243.86M and net income of $87.01M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Keros Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Keros Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$243.86M$0$151.00K$0$20.10M$0$10.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$67.57M-$210.83M-$169.94M-$114.79M-$56.37M-$46.66M-$10.56M
Net income$87.01M-$187.35M-$152.99M-$104.68M-$58.74M-$45.36M-$12.34M
Research & development$129.64M$173.63M$135.26M$87.26M$55.14M$33.86M$17.38M
Weighted-average diluted sharesshares 37.86Mshares 37.44Mshares 29.45Mshares 25.24Mshares 23.33Mshares 15.51MUnavailable
Pretax income$91.90M-$187.05M-$152.99M-$104.68M-$56.73M-$45.53M-$12.34M
Income tax expense$4.88M$300.00K$0$0$2.01M-$172.00K$0
Diluted EPS$2.30$-5.00$-5.20$-4.15$-2.52$-2.93Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$46.85M$40.75M$34.83M$27.52M$21.33M$12.80M$3.18M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Keros Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$287.42M$559.93M$331.15M$279.05M$230.04M$265.88M$7.02M
Total assets$338.02M$615.89M$370.02M$306.78M$255.25M$269.44M$10.96M
Current assets$315.43M$588.89M$347.29M$285.77M$251.44M$267.73M$8.93M
Total liabilities$34.89M$44.33M$37.81M$29.36M$12.08M$7.72M$10.46M
Current liabilities$20.41M$27.45M$24.37M$16.55M$11.85M$7.18M$4.49M
Total equity incl. NCI$303.13M$571.55M$332.21M$277.42M$243.17M$261.72M-$19.45M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$19.94M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$3.57M$2.74M$143.00K$0$18.00M$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.97M$4.60M$5.45M$3.34M$3.64M$2.15M$2.09M

Cash flow

Keros Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow$107.50M-$160.87M-$124.51M-$70.06M-$62.15M-$36.89M-$16.00M
Capital expenditures$1.55M$1.93M$2.46M$1.24M$1.02M$294.00K$271.00K
Investing cash flow-$1.55M-$1.93M-$2.46M-$1.24M-$1.02M-$294.00K-$271.00K
Financing cash flow-$378.47M$391.82M$178.96M$120.31M$28.55M$296.04M$14.00K
Net change in cash-$272.52M$229.02M$51.98M$49.01M-$34.62M$258.86M-$16.26M
Stock-based compensation$28.70M$34.87M$28.76M$18.68M$11.72M$4.10M$59.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$375.00M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Keros Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow$105.95M-$162.80M-$126.97M-$71.30M-$63.17M-$37.19M-$16.27M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin27.7%Unavailable-112543.7%Unavailable-280.5%Unavailable-105.6%
FCF margin43.4%Unavailable-84087.4%Unavailable-314.3%Unavailable-162.7%
SBC / revenue11.8%Unavailable19048.3%Unavailable58.3%Unavailable0.6%
Current ratio15.45x21.45x14.25x17.27x21.23x37.27x1.99x
Revenue YoY growthUnavailable-100.0%Unavailable-100.0%Unavailable-100.0%Unavailable
Net margin35.7%Unavailable-101319.2%Unavailable-292.3%Unavailable-123.4%
R&D / revenue53.2%Unavailable89574.8%Unavailable274.3%Unavailable173.8%
CapEx / revenue0.6%Unavailable1631.8%Unavailable5.1%Unavailable2.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate5.3%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KROS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.